oxyfedrine and Angina-Pectoris

Topics: Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Digitalis Glycosides; Humans; Lidoflazine; Oxyfedrine; Perhexiline; Practolol; Prenylamine; Verapamil

The comparative efficacy and safety of oxyfedrine and propranolol in the management of angina pectoris was evaluated in a double-blind randomized cross-over study. Out of 21 patients registered, 14 completed the study. Three patients dropped out due to poor response and 4 were lost to follow up. Both the drugs i.e. oxyfedrine (8-24 mg three times a day) and propranolol (40-80 mg three times a day) produced a significant reduction in the incidence of anginal attacks and the consumption of nitroglycerine tablets. Propranolol produced a better response than oxyfedrine although the difference was not significant. This may be due to the small sample size. No change in heart rate and rate-pressure product was observed with oxyfedrine, in contrast to that seen with propranolol. The beneficial effect of treatment on exercise tolerance and ST-segment depression was more marked with propranolol. No significant change in laboratory parameters was observed with either drug.

Topics: Angina Pectoris; Animals; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Exercise Test; Female; Humans; Male; Middle Aged; Oxyfedrine; Propiophenones; Propranolol; Random Allocation

We have compared oxyfedrine 24 mg four times daily with atenolol 100 mg once daily in the relief of angina pectoris in a double-blind cross-over study; assessments were by diary cards and treadmill testing. Both oxyfedrine and atenolol reduced the frequency of angina by similar amounts and both produced similar improvements in treadmill performance. Side effects were infrequent and minor with both drugs. The model of action of oxyfedrine appears to be different from atenolol. Oxyfedrine allows the double product of systolic blood pressure X heart rate at peak exercise to be maintained at levels similar to those with placebo; the double product at peak exercise is significantly less with atenolol.

Topics: Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Oxyfedrine; Propiophenones; Random Allocation

In an open multicentre trial, the clinical efficacy and tolerance of Oxyfedrine, (Ildamen forte) was evaluated in 123 patients with angina pectoris. After three months of treatment the frequency of anginal attacks and nitroglycerin consumption were markedly reduced in 80 percent, after 12 months in 88% of patients; 37 percent were totally angina-free and 50% were without need for sublingual nitroglycerin. Side-effects were reported by 23.6% of patients during the first months of treatment with a total of eight symptoms being reported in 40 instances; after one year, the incidence of side-effects was substantially reduced to 8 instances in 6 percent of patients. Laboratory investigation were not significantly affected: in 11 patients minor deviations from the reference range were noted without clinical relevance. Dropouts due do drug intolerance were not observed.

Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Coronary Circulation; Coronary Disease; Female; Humans; Long-Term Care; Male; Middle Aged; Oxyfedrine; Propiophenones

Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Isosorbide Dinitrate; Male; Middle Aged; Oxyfedrine; Propiophenones; Propranolol

Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Humans; Middle Aged; Myocardial Contraction; Oxyfedrine; Placebos; Propiophenones; Propranolol

1 In a group of 23 patients with documented ischaemic heart disease who experienced angina pectoris, oral oxyfedrine (24 mg three times daily) was compared with isosorbide dinitrate (10 mg three times daily) and placebo in a double-blind double-crossover clinical trial. 2 Isosorbide dinitrate appeared no better than placebo, either in terms of symptomatic relief or ECG responses to exercise. Thirty eight per cent of patients complained of headaches and 28% had to cease taking the drug for this reason. 3 Oxyfedrine produced statistically significant improvements in both symptom level (P < 0.01) and ECG ST-segment responses to exercise (P < 0.01). The only side effect noted was a reversible loss of taste sensation by one patient. 4 Neither drug produced any adverse changes in any haematological or biochemical parameters. 5 Oxyfedrine is, therefore, to be preferred to isosorbide dinitrate, being both much better tolerated and more efficacious.

Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Exercise Test; Female; Headache; Heart Rate; Humans; Isosorbide Dinitrate; Male; Middle Aged; Oxyfedrine; Placebos; Propiophenones

In contrast to the drug testing under clinical conditions, many other problems appear in regard to outpatients. These investigations were carried out on 49 outpatients with various degrees of angina pectoris under the conditions of an intraindividual comparison with d,l-oxyfedrine (Myofedrin), l-oxyfedrine (ildamen) or placebo for a period of 16 weeks and a daily dose of 48 mg applied orally altogether. The severity degrees of the angina pectoris were diminished after the chronic application of l- and d,l-oxyfedrine. There are no differences in the activity and side-effects.

Topics: Ambulatory Care; Angina Pectoris; Clinical Trials as Topic; Humans; Oxyfedrine

1 A double-blind-crossover randomised trial was performed to compare the effects of oxyfedrine (maximum dose 32 mg three times daily), propranolol (maximum dose 120 mg three times daily) and placebo in 30 patients with chronic stable angina pectoris. Assessment was by means of symptom level, ECG responses to graded exercise and haematological and biochemical investigation. 2 Oxyfedrine and propranolol resulted in similar significant improvements in symptom level (P < 0.05 in both cases), and ST index (propranolol P < 0.02; oxyfedrine P < 0.05). Neither drug produced any significant changes in haematologaical or biochemical investigations and only infrequent minor side effects were noted. 3 These results indicate that oxyfedrine is a safe and well-tolerated drug with an efficacy comparable with that of propranolol in the treatment of patients with angina pectoris.

Topics: Adult; Aged; Angina Pectoris; Double-Blind Method; Drug Evaluation; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Oxyfedrine; Placebos; Propiophenones; Propranolol

Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Oxyfedrine; Placebos; Propiophenones

Medical treatment of angina pectoris is largely based on the use of beta-blocking agents, calcium antagonists, and nitrates. Oxyfedrine, an amino ketone derivative and partial agonist at beta receptors, has been shown to have potent antianginal properties and to increase coronary blood flow in normal and ischemic myocardial regions in experimental studies. We assessed the effects of intravenous oxyfedrine on regional myocardial blood flow, using positron emission tomography (15-oxygen water), in six patients with chronic stable angina, positive exercise tests, and documented coronary artery disease. Myocardial blood flow was measured in all patients before (baseline) and 10 minutes after the intravenous administration of a single bolus (0.11-0.13 mg/kg) of oxyfedrine. Compared to baseline, heart rate and systolic blood pressure remained almost unchanged after the administration of oxyfedrine. Mean baseline myocardial blood flow was 0.90 +/- 0.15 ml/g/min in areas supplied by arteries with significant coronary stenosis and 1.08 +/- 0.19 ml/g/min in areas supplied by nonstenotic coronary vessels (p less than 0.05). After the administration of oxyfedrine, myocardial blood flow increased significantly in both the regions supplied by stenotic vessels (by 25%; from 0.90 +/- 0.15 to 1.20 +/- 0.31 ml/g/min; p = 0.002) and in areas supplied by angiographically normal coronary vessels (by 22%; from 1.08 +/- 0.19 to 1.38 +/- 0.49 ml/g/min; p less than 0.05). The results of this study indicate that in patients with coronary artery disease, intravenous oxyfedrine significantly increases regional myocardial blood flow, both in areas supplied by critically obstructed vessels and in areas supplied by normal or less severely narrowed coronary arteries.

Topics: Aged; Angina Pectoris; Coronary Circulation; Coronary Disease; Female; Humans; Male; Middle Aged; Oxyfedrine; Regional Blood Flow; Tomography, Emission-Computed

Experience in the treatment of over 500 chronic coronary patients with various anti-anginal drugs or their combinations is summarized. Controlled (double blind) and open studies and acute pharmacologic tests demonstrated comparative efficacy of depot-nitrates, beta-blockers, oxyfedrine, cordaron, lidoflazinum, molsidamine (corvaton). The effects on exercise tolerance (bicycle ergometry) with isolated and combined use of the drugs are described. Indications for surgery are discussed.

Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Drug Evaluation; Drug Therapy, Combination; Electrocardiography; Exercise Test; Humans; Male; Middle Aged; Molsidomine; Nitroglycerin; Oxyfedrine; Propranolol; Sydnones; Vasodilator Agents

Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angina Pectoris; Heart; Humans; Oxyfedrine; Propiophenones

Topics: Angina Pectoris; Animals; Hemodynamics; Humans; Oxyfedrine; Propiophenones

The experiments on dogs showed that in chronic myocardial ischaemia nonachlasine raising the retrograde arterial pressure and increasing the retrograde blood inflow to the ischaemic focus exerts a positive influence on the collateral cardiac haemodynamics. Raising the tonus of the coronary vessels in the intact regions of the myocardium to a greater extent than in the ischaemic region, nonachlasine redistributes the bloodflow to the advantage of the ischaemic zone. Oxyphedrin, decreasing of the ischaemic zone. Oxyphedrin, decreasing the tonus of the coronaries, especially in the intact areas of the myocardium, elicits the syndrome of "stealing" the zone of ischaemia.

Topics: Adrenergic beta-Agonists; Angina Pectoris; Animals; Chronic Disease; Collateral Circulation; Coronary Circulation; Coronary Disease; Dogs; Nonachlazine; Oxyfedrine; Regional Blood Flow; Vasodilator Agents

Topics: Angina Pectoris; Animals; Dogs; Oxyfedrine; Propiophenones; Vasodilation

Topics: Adult; Aged; Angina Pectoris; Cardiac Output; Cineangiography; Female; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Oxyfedrine; Propiophenones

Topics: Adult; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Oxyfedrine; Propiophenones

Topics: Adult; Aged; Angina Pectoris; Drug Evaluation; Humans; Male; Middle Aged; Nitroglycerin; Oxyfedrine; Propiophenones

In a study of patients with angina pectoris the influence of coronary-effective medicaments on the concentration of non-esterified fatty acids was investigated. Supplementary establishments were carried out experimentally on pigs. Compared with normal persons patients with angina pectoris had a significantly higher level of non-esterified fatty acids. In an oral dose of 150 mg a day propranolol decreased the non-esterified fatty acids to normal values. Dipyridamol decreased the concentration of non-esterified fatty acids in the serum in an average dose of 450 mg a day also significantly. The combination of propranolol and dipyridamol did not evoke a particular additive effect on the decrease of non-esterified fatty acids. In a dosage of 300 mg a day orally trapymin had no clear influence on the non-esterified fatty acids. D,L-oxyfedrin (64 mg orally a day) increased the concentration of the non-esterified fatty acids in the serum. The decrease of the level of non-esterified fatty acids seems important for the prophylaxis of the infarction. The antilipolytic effect is a desirable therapeutic mechanism among others in the coronary therapy.

Topics: Angina Pectoris; Animals; Dipyridamole; Drug Combinations; Fatty Acids, Nonesterified; Humans; Oxyfedrine; Propanolamines; Propranolol; Swine; Time Factors; Trapidil; Vasodilator Agents

Topics: Adrenergic beta-Antagonists; Ambulatory Care; Analgesics; Angina Pectoris; Anticoagulants; Coronary Disease; Humans; Hypnotics and Sedatives; Myocardial Infarction; Nitrites; Oxyfedrine; Time Factors